Advances in Drug Discovery and Development

USD 950

* Required Fields

USD 950

PAY BY INVOICE

Be the first to review this product

This Drug Discovery TechVision Opportunity Engine (TOE) provides insights across research advances in gene editing technologies that have enabled enhanced drug screening and target discovery. Furthermore, the service also includes regulatory advances for 3,4-methlyenedioxymethamaphetamine and Ibrutinib therapies. Interestingly, the TOE encompasses advances in novel target discovery for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD). Lastly, the TOE summarizes key technologies and trends fueling the growing use of Big Data for drug discovery applications.

The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.

The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Gene editing, CRISPR, drug discovery, drug screening, cancer immunotherapy, immune checkpoint inhibitor, lentivirus transduction, synthetic lethality, posttraumatic stress disorder, MDMA, chronic graft-versus-host-disease, Imbruvica, tyrosine kinase inhibitor, neurodegenerative diseases, Alzheimer’s disease, amyotrophic lateral sclerosis, Big Data, predictive analytics, artificial intelligence, cloud computing

Table of Contents

Advances in Drug Discovery and DevelopmentRecent Innovations in Drug DiscoveryHigh-throughput Knock-out Screens Speeding Up Target DiscoveryDeleting Tumor Genes Using CRISPR-Cas9 Gene Editing TechnologyVirus-like Particles Increasing Lentivirus Transduction for Drug ScreeningAddressing Novel Targets for Genetically Defined CancersBreakthrough Therapy Designation for Ecstasy DrugFirst FDA-Approved Therapy for the Treatment of Chronic Graft Versus Host DiseaseNew Therapeutic Target Discovered for Chronic Neurodegenerative DiseasesDrug DiscoveryTechnology Focus and TrendsTechnology Focus and TrendsThree Start-up Companies to WatchIndustry InteractionsIndustry Interactions (continued)




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 08-Dec-17

Region : Global

Release Date : 08-Dec-17

Region : Global

Release Date : 01-Dec-17

Region : Global

Release Date : 29-Nov-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.